Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Table 4

Analysis of factors influencing HEHDS-guided CR in AML.

Factors		Total CR%	CR rate/non-HEHDS guided (%)	CR rate/HEHDS guided (%)	values
Mutation	TP53	3/5 (60)	1/2 (50)	2/3 (66.67)	0.667
	KIT	5/12 (41.67)	1/2 (50)	4/10 (40)	0.682
	NRAS	5/20 (25)	1/6 (16.67)	4/14 (28.57)	0.517
	FLT3-ITD	9/23 (39.13)	1/6 (16.67)	8/17 (47.06)	0.208
Median WBC count		38/93 (40.9)	9/29 (31)	29/64 (45.3)	0.142
		10/28 (35.7)	0/7 (0)	10/21 (47.6)	0.027
Median marrow blast %	<10	28/54 (51.9)	5/14 (35.7)	23/40 (57.5)	0.137
	≥10	20/67 (30)	4/22 (18.2)	16/45 (35.6)	0.119